BR9500380A - Composto composição farmacêutica método para bloquear sítios do receptor de NMDA e método de tratamento de uma doença ou estado num manífero - Google Patents

Composto composição farmacêutica método para bloquear sítios do receptor de NMDA e método de tratamento de uma doença ou estado num manífero

Info

Publication number
BR9500380A
BR9500380A BR9500380A BR9500380A BR9500380A BR 9500380 A BR9500380 A BR 9500380A BR 9500380 A BR9500380 A BR 9500380A BR 9500380 A BR9500380 A BR 9500380A BR 9500380 A BR9500380 A BR 9500380A
Authority
BR
Brazil
Prior art keywords
treating
manifer
disease
pct
condition
Prior art date
Application number
BR9500380A
Other languages
English (en)
Inventor
Todd W Butler
Bertrand L Chenard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9500380A publication Critical patent/BR9500380A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9500380A 1994-01-31 1995-01-30 Composto composição farmacêutica método para bloquear sítios do receptor de NMDA e método de tratamento de uma doença ou estado num manífero BR9500380A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31

Publications (1)

Publication Number Publication Date
BR9500380A true BR9500380A (pt) 1995-10-17

Family

ID=22697514

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9408506A BR9408506A (pt) 1994-01-31 1994-11-21 Compostos neuroprotetores
BR9500380A BR9500380A (pt) 1994-01-31 1995-01-30 Composto composição farmacêutica método para bloquear sítios do receptor de NMDA e método de tratamento de uma doença ou estado num manífero

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9408506A BR9408506A (pt) 1994-01-31 1994-11-21 Compostos neuroprotetores

Country Status (27)

Country Link
US (1) US5744483A (pt)
EP (1) EP0741724B1 (pt)
JP (1) JP2866743B2 (pt)
CN (1) CN1048247C (pt)
AT (1) ATE183184T1 (pt)
AU (1) AU684568B2 (pt)
BR (2) BR9408506A (pt)
CA (1) CA2182101C (pt)
CO (1) CO4230161A1 (pt)
CZ (1) CZ286757B6 (pt)
DE (1) DE69420053T2 (pt)
DK (1) DK0741724T3 (pt)
EG (1) EG20672A (pt)
ES (1) ES2134361T3 (pt)
FI (1) FI113769B (pt)
GR (1) GR3031356T3 (pt)
HU (1) HU221633B1 (pt)
IL (1) IL112415A (pt)
MY (1) MY111623A (pt)
NO (1) NO309190B1 (pt)
NZ (1) NZ275151A (pt)
PE (1) PE43795A1 (pt)
PL (1) PL179448B1 (pt)
RU (1) RU2126404C1 (pt)
TW (1) TW449591B (pt)
WO (1) WO1995020587A1 (pt)
ZA (1) ZA95692B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509839A (ja) * 1995-09-15 1999-08-31 ファイザー・インコーポレーテッド 薬剤活性を有するフェノール誘導体
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
ES2347152T3 (es) * 2003-11-26 2010-10-26 Pfizer Products Inc. Derivados de aminopirazol como inhibidores de gsk-3.
NZ567285A (en) 2005-11-03 2010-06-25 Hoffmann La Roche Arylsulfonylchromans as 5-HT6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
AU2007207481B2 (en) * 2006-01-20 2012-08-23 Merck Sharp & Dohme Corp. Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
EP2522647B1 (en) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Process of separating chiral isomers of chroman compounds and their derivatives and precursors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (pt) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (en) * 1978-07-03 1980-02-07 Sandoz Ag 3-aminopropoxy-aryl derivates,preparation and use thereof
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0076075B1 (en) * 1981-09-25 1986-11-20 Beecham Group Plc Pharmaceutically active benzopyran compounds
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
HU222726B1 (hu) * 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
CN1048247C (zh) 2000-01-12
NO963186L (no) 1996-07-30
CZ286757B6 (en) 2000-06-14
WO1995020587A1 (en) 1995-08-03
MY111623A (en) 2000-09-27
TW449591B (en) 2001-08-11
CZ225696A3 (en) 1997-01-15
ATE183184T1 (de) 1999-08-15
CO4230161A1 (es) 1995-10-19
GR3031356T3 (en) 2000-01-31
FI950403A (fi) 1995-08-01
CA2182101A1 (en) 1995-08-03
JPH09501698A (ja) 1997-02-18
ES2134361T3 (es) 1999-10-01
DK0741724T3 (da) 1999-12-20
US5744483A (en) 1998-04-28
EP0741724A1 (en) 1996-11-13
PE43795A1 (es) 1995-12-09
NO309190B1 (no) 2000-12-27
AU8066394A (en) 1995-08-15
HU221633B1 (hu) 2002-12-28
NO963186D0 (no) 1996-07-30
FI950403A0 (fi) 1995-01-30
HU9602100D0 (en) 1996-09-30
CA2182101C (en) 1999-08-03
EP0741724B1 (en) 1999-08-11
CN1142825A (zh) 1997-02-12
NZ275151A (en) 1998-02-26
RU2126404C1 (ru) 1999-02-20
FI113769B (fi) 2004-06-15
DE69420053T2 (de) 1999-11-25
PL315681A1 (en) 1996-11-25
EG20672A (en) 1999-11-30
IL112415A0 (en) 1995-03-30
ZA95692B (en) 1996-07-30
IL112415A (en) 1999-07-14
PL179448B1 (pl) 2000-09-29
BR9408506A (pt) 1997-08-05
DE69420053D1 (de) 1999-09-16
AU684568B2 (en) 1997-12-18
HUT75942A (en) 1997-05-28
JP2866743B2 (ja) 1999-03-08

Similar Documents

Publication Publication Date Title
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
BR0110420A (pt) Agonistas muscarìnicos
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR9500380A (pt) Composto composição farmacêutica método para bloquear sítios do receptor de NMDA e método de tratamento de uma doença ou estado num manífero
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
HUP9902135A2 (hu) (+)-alfa-(2,3-Dimetoxi-fenil)-1-[2-(4-fluor-fenil)-etil]-4-piperidin-metanol alkalmazása depresszív és bipoláris rendellenességek kezelésére alkalmas gyógyszerkészítmény előállítására
BR9502072A (pt) Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica
CA2473694A1 (en) Use of calmodulin to promote bone regeneration
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
HUT57040A (en) Process for producing pharmaceutical compositions comprising 2-brackets open 4-(4-chlorophenyl)-cyclohexyl brackets closed-3-hydroxy-1,4-naphthoquinone suitable for treating toxoplasmosis
GB9216859D0 (en) Medicaments
NO20091111L (no) Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser
Iftikhar et al. Comparing the Effect of Combination of 1% Metronidazole and 0.25% Chlorhexidine Gluconate Gel with 1.5% Metronidazole and 0.5% Chlorhexidine Gluconate Gel in the Treatment of Chronic Periodontitis: A Randomized, Single-Blind, Split-Mouth Study
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A,12A,13A E 14A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1971 DE 14/10/2008.